Edition:
United Kingdom

AstraZeneca Q1 Core EPS $0.89, Affirms FY Forecast


Friday, 26 Apr 2019 

April 26 (Reuters) - AstraZeneca PLC ::AZN: Q1 2019 RESULTS.REITERATES ITS FY 2019 GUIDANCE.QTRLY REPORTED EPS OF $0.47.ANTICIPATES PRODUCTIVITY GAINS AND OPERATING LEVERAGE IN FY 2019.QTRLY CORE EPS $0.89.CORE OPERATING PROFIT IS ANTICIPATED TO GROW AT A FASTER RATE THAN PRODUCT SALES IN FY 2019.QTRLY TOTAL REVENUE $5,491 MILLION VERSUS $5,178 MILLION AS REPORTED A YEAR EARLIER.QTRLY PRODUCT SALES $5,465 MILLION VERSUS $ 4,985 MILLION AS REPORTED A YEAR EARLIER.SEES STRONG, SUSTAINABLE PRODUCT SALES GROWTH TO BE ACCOMPANIED BY OPERATING LEVERAGE, LEADING TO IMPROVEMENT IN PROFITABILITY IN FY.IF FX RATES WERE TO REMAIN AT AVERAGE OF RATES SEEN IN JAN-MARCH, SEES LOW SINGLE-DIGIT PERCENT ADVERSE IMPACT ON PRODUCT SALES & CORE EPS.QTRLY EMERGING MARKETS SALES INCREASED BY 14% (22% AT CER); CHINA SALES INCREASED BY 21% (28% AT CER).IN FY 2019, CASH PERFORMANCE EXPECTED TO BE ADVERSELY IMPACTED BY ONE-OFF PAYMENTS RELATING TO PRIOR BUSINESS-DEVELOPMENT DEALS.PRODUCT SALES GROWTH IN QUARTER REFLECTED SUCCESS OF OUR NEW MEDICINES AND EMERGING MARKETS.IN ONCOLOGY, TAGRISSO, IMFINZI AND LYNPARZA CONTINUED TO DO WELL AND, IN BIOPHARMA, FARXIGA, BRILINTA AND FASENRA ALSO GREW STRONGLY.QTRLY GLOBAL ONCOLOGY SALES INCREASED BY 54%.